We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
-1.34%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$348M
AUM Growth
-$15.4M
Cap. Flow
+$604K
Cap. Flow %
0.17%
Top 10 Hldgs %
35.81%
Holding
95
New
24
Increased
19
Reduced
22
Closed
25

Top Buys

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$12.6M
2
PFE icon
Pfizer
PFE
+$11.1M
3
HOLX
Hologic
HOLX
+$9M
4
APLS
Apellis Pharmaceuticals
APLS
+$8.71M
5
LFST icon
Lifestance Health
LFST
+$6.74M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$12.1M
2
CYTK icon
Cytokinetics
CYTK
+$11M
3
ELV icon
Elevance Health
ELV
+$9.5M
4
SNY icon
Sanofi
SNY
+$9.22M
5
LHCG
LHC Group LLC
LHCG
+$8.41M

Sector Composition

Rank Sector Weight
1 Healthcare 97.71%
2 Energy 0%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSP icon
51
Inspire Medical Systems
INSP
$1.71B
$2.33M 0.67%
+10,000
New +$2.09M
RGNX icon
52
Regenxbio
RGNX
$703M
$2.31M 0.66%
+55,000
New +$1.98M
ZY
53
DELISTED
Zymergen Inc. Common Stock
ZY
$2.11M 0.61%
+160,000
New +$3.39M
LYEL icon
54
Lyell Immunopharma
LYEL
$365M
$2.07M 0.6%
+7,000
New +$2.1M
AKRO
55
DELISTED
Akero Therapeutics
AKRO
$1.9M 0.55%
85,000
– –
IMGN
56
DELISTED
Immunogen Inc
IMGN
$1.7M 0.49%
+300,000
New +$1.73M
LXRX icon
57
Lexicon Pharmaceuticals
LXRX
$1.08B
$1.68M 0.48%
+350,000
New +$1.44M
MYOV
58
DELISTED
Myovant Sciences Ltd.
MYOV
$1.46M 0.42%
65,000
-20,000
-24% -$439K
ZYME icon
59
Zymeworks
ZYME
$1.73B
$1.45M 0.42%
+50,000
New +$1.66M
DTIL icon
60
Precision BioSciences
DTIL
$207M
$1.44M 0.41%
4,167
-1,666
-29% -$565K
RVNC
61
DELISTED
Revance Therapeutics, Inc.
RVNC
$1.39M 0.4%
+50,000
New +$1.43M
BMRN icon
62
BioMarin Pharmaceuticals
BMRN
$13.5B
$1.39M 0.4%
18,000
-7,000
-28% -$552K
FMTX
63
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$1.39M 0.4%
60,000
+15,000
+33% +$355K
KURA icon
64
Kura Oncology
KURA
$882M
$1.12M 0.32%
60,000
-10,000
-14% -$188K
AVIR icon
65
Atea Pharmaceuticals
AVIR
$404M
$1.05M 0.3%
+30,000
New +$832K
AGIO icon
66
Agios Pharmaceuticals
AGIO
$1.95B
$923K 0.27%
20,000
-10,000
-33% -$483K
DNTH icon
67
Dianthus Therapeutics
DNTH
$6.07B
$655K 0.19%
5,625
+937
+20% +$109K
PTGX icon
68
Protagonist Therapeutics
PTGX
$9.6B
$620K 0.18%
+35,000
New +$1.49M
CMRX
69
DELISTED
Chimerix, Inc.
CMRX
$557K 0.16%
90,000
+15,000
+20% +$103K
LBPH
70
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$266K 0.08%
30,000
– –
A icon
71
Agilent Technologies
A
$42.2B
– –
-40,000
Closed -$5.91M
ALEC icon
72
Alector
ALEC
$233M
– –
-35,000
Closed -$729K
ALKS icon
73
Alkermes
ALKS
$8.26B
– –
-150,000
Closed -$3.68M
ALT icon
74
Altimmune
ALT
$583M
– –
-160,000
Closed -$1.58M
ARDX icon
75
Ardelyx
ARDX
$982M
– –
-70,000
Closed -$531K
1 2
3
4

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return

Integral Health Asset Management's Q3 2021 Portfolio in Review

As of Q3 2021, Integral Health Asset Management held 95 positions worth $348M, down 4.2% from $363M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Integral Health Asset Management's Q3 2021 filing shows 24 new, 19 increased, 22 reduced and 25 closed positions. Its largest new stake was CVS Health: 150,000 shares worth $12.7M. The largest sale was Biogen, an estimated $12.1M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 93% a quarter earlier, followed by Energy and Industrials.

  • Integral Health Asset Management's largest Q3 2021 buy was CVS Health: 150,000 shares worth $12.7M.
  • Integral Health Asset Management added most to Apellis Pharmaceuticals in Q3 2021, an estimated $8.71M increase.
  • Integral Health Asset Management's biggest Q3 2021 reduction was Cytokinetics, cutting an estimated $11M.
  • Integral Health Asset Management fully exited Biogen in Q3 2021, selling an estimated $12.1M.
  • Integral Health Asset Management's ten largest holdings make up 36% of its $348M portfolio in Q3 2021.
  • Integral Health Asset Management opened 24 new positions and closed 25 in Q3 2021.
  • Integral Health Asset Management's portfolio value fell 4.2% quarter-over-quarter to $348M.

Based on Integral Health Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.